RAC 2.20% $1.78 race oncology ltd

Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-50

  1. 1,179 Posts.
    lightbulb Created with Sketch. 232
    "Yes an interesting coincidence with both RAC & IMU releasing clinical data results on the same day. It is interesting to note how different the style of the two releases are from each other."

    My main focus is the results of the relative trials, and from my reading each appears very promising, which is excellent news for patients, existing and future, and good news for shareholders of each.

    Is that your assessment of each trial results?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.